1 Genes associated with depression and coronary artery disease are enriched for 2 inflammation and cardiomyopathy-associated pathways. Kritika Singh^{1,2}, Hyunjoon Lee^{3,4,5*}, Julia M Sealock^{1,2*}, Tyne Miller-Flemming^{1,2}, Peter 3 Straub^{1,2}, Nancy J. Cox^{1,2}, Quinn S. Wells⁶, Jordan M. Smoller^{3,4,5}, Emily C. Hodges^{2,7}, Lea 4 K. Davis^{1,2,8,9,10} 5 6 *These authors contributed equally 7 #Corresponding author 8 ¹Division of Genetic Medicine, Department of Medicine 9 Vanderbilt University Medical Center 10 Nashville, TN, 37232, USA 11 12 ²Vanderbilt Genetics Institute 13 Vanderbilt University Medical Center 14 Nashville, TN, 37232, USA 15 16 ³Psychiatric and Neurodevelopmental Genetics Unit 17 Center for Genomic Medicine 18 Massachusetts General Hospital 19 Boston, MA, 02114, USA 20 21 ⁴Center for Precision Psychiatry 22 Department of Psychiatry 23 Massachusetts General Hospital 24 Boston, MA, 02114, USA 25 26 ⁵Stanley Center for Psychiatric Research 27 Broad Institute of Harvard and MIT 28 Cambridge, MA, 02114, USA 29 30 ⁶Division of Cardiovascular Medicine, Department of Medicine, 31 Vanderbilt University Medical Center, 32 Nashville, TN, 37232, USA 33 34 ⁷Department of Biochemistry. Vanderbilt University School of Medicine, 35

36 Nashville, TN, 37232, USA 37 38 ⁸Department of Molecular Physiology and Biophysics 39 Vanderbilt University Medical Center 40 Nashville, TN, 37232, USA 41 42 ⁹Department of Psychiatry and Behavioral Sciences 43 Vanderbilt University Medical Center 44 Nashville, TN, 37232, USA 45 46 ¹⁰Departments of Medicine and Biomedical Informatics 47 Vanderbilt University Medical Center 48 Nashville, TN, 37232, USA 49 Total word count of manuscript: 4,656 Words 50 51 52 Short Title: Genes shared between depression and CAD 53

55

56

57

58

59

60

61

62

63

64

65

66

67

68

Abstract (140 words) Background: Depression and Coronary Artery Disease (CAD) are highly comorbid conditions. Approximately 40% of individuals who have one diagnosis will also develop the other within their lifetime. Prior research indicates that polygenic risk for depression increases the odds of developing CAD even in the absence of clinical depression. However, the specific genes and pathways involved in comorbid depression-CAD remain unknown. Results: We identified genes that are significantly associated with both depression and CAD, and are enriched for pathways involved in inflammation and for previous association with cardiomyopathy. We observed increased rate of prevalent, but not incident, cardiomyopathy cases in individuals with comorbid depression-CAD compared to those with CAD alone in three electronic large health record (EHR) datasets. Conclusions: The results of our study implicate genetically regulated inflammatory mechanisms in depression-CAD. Our results also raise the hypothesis that depression-associated CAD may be enriched for cardiomyopathy.

69 **Clinical Perspective** 70 A. What's New? 71 1. Gene associations shared between depression and CAD are enriched for prior 72 association with cardiomyopathy phenotypes. 73 2. Cardiomyopathy is significantly more prevalent in individuals with comorbid 74 depression-CAD than in CAD or depression alone. B. What are the Clinical Implications? 75 1. Our work suggests that individuals with comorbid depression-CAD may benefit from 76 77 screening for cardiomyopathy. 78

Non-Standard Abbreviations and Acronyms

79

Abbreviation	Definition
CAD	Coronary artery disease
CI	Confidence interval
CAD	Coronary Artery Disease
CVD	Cardiovascular disease
EHR	Electronic health record
GWAS	Genome-wide association study
ICD	International Classification of Diseases
LD	Linkage disequilibrium
MD	Major depression
MDD	Major depressive disorder
MHC	Major histocompatibility complex
MR	Mendelian randomisation
OR	Odds ratio
PGS	Polygenic score
SNP	Single nucleotide polymorphism
VUMC	Vanderbilt University Medical Center

Introduction

Chronic complex diseases such as cardiovascular disease (CVD) are the primary drivers of premature death among individuals with psychiatric disorders. Approximately 17 to 44 percent of patients with coronary artery disease (CAD), the most common type of CVD, also have a diagnosis of major depression (MDD), a common mental health diagnosis¹. Several studies suggest that these two conditions are biologically related. A diagnosis of major depression is associated with increased 18-month cardiac mortality among CAD patients; and CAD with comorbid MDD reduces lifespan by 15-20 years²⁻⁵. However, despite the frequency and high mortality rate of comorbid CAD with depression and/or MDD, hereafter referred to as (major) depressive CAD or (m)dCAD, the biological relationship between these conditions remains poorly understood.

Previously, we demonstrated that common genetic risk for depression identified by genome-wide association studies (GWAS) and quantified in the form of polygenic risk scores (PRS), is associated with a diagnosis of CAD and myocardial infarction in a healthcare-based clinical population⁶. High genetic liability to MDD was associated with increased risk of cardiovascular disease even among patients with no history of psychiatric illness and after accounting for cardiovascular disease risk factors⁶. Shared inflammatory processes provide one possible explanation for these findings^{7,8}. Studies show that as CAD progresses, changes in the levels of inflammatory biomarkers such as C-Reactive protein (CRP), leukocytes, monocytes and inflammation associated prothrombotic markers including platelets, can be observed^{9–11}. Similarly, onset and severity of depression is associated with changes in the levels of immune and inflammatory factors including leukocytes, CRP, and platelets^{12–22}. Neuroinflammation and

peripheral inflammation are hypothesized to play an important role in both MDD and CAD respectively, providing a potential common biological pathway that may link neuroinflammation in depression together with atherosclerotic inflammation in CAD^{7,8}.

Consortium efforts over the past decade have yielded results from large genome-wide association studies of depression, and independently, CAD^{23,24}. These studies provide a map of statistical associations between common single nucleotide polymorphisms (SNPs) and each diagnosis, respectively. However, the genes that are implicated by these SNP associations must also be identified to define the biological pathways that might be shared between these conditions. Transcriptome wide association scans (TWAS) employ functional data to map SNPs to genes based on their ability to regulate gene expression²⁵. In this study, we first used the TWAS method S-MultiXcan to map depression and CAD SNP-associations to the genes they regulate using cross-tissue expression quantitative trait loci (eQTL) annotations²⁵. We then performed a series of enrichment and pathway analyses to characterize the gene set that was significantly associated with both depression and CAD. Our findings suggest that genes associated with both CAD and depression are enriched for both inflammatory pathways and genes previously associated with cardiomyopathy.

Next, we developed a clinical hypothesis based on these findings and tested it in three separate large electronic health records (EHR) data sets –Vanderbilt University Medical Center EHR, All of Us Research Program, and Mass-General Brigham EHR. At each site, we find that the rate of prevalent cardiomyopathy is significantly higher in subjects with (m)dCAD compared to those with CAD alone. Taken together, results of our study link depression and CAD through

genetically controlled inflammatory mechanisms, and further suggest a relationship between (m)dCAD and cardiomyopathy.

Materials and Methods

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

Genome-wide Association Study Data – Coronary Artery Disease

We utilized publicly available summary statistics from a recently published GWAS of CAD as the foundation for our MetaXcan and S-MultiXcan analyses²³. This study included a genome-wide meta-analysis of CAD cases and controls from the UK Biobank (UKBB) and CARDIOGRAMplusC4D²³. CAD was defined in the UKBB by ICD10 codes (I21 – I25), procedural codes (K40-K46, K49, K50 and K75), and self-report of heart attack/myocardial infarction, coronary angioplasty +/- stent, coronary artery bypass graft surgery, or triple heart bypass. Controls were defined by the absence of features used to define cases and the absence of any family history of "heart disease". Application of these criteria resulted in 34,541 CAD cases and 261,984 controls. The second sample used in this meta-analysis was the CARDIoGRAMplusC4D GWAS which itself was a meta-analysis of twenty-eight studies of European or South Asian descent populations. CAD was operationally defined differently across the cohorts, but all definitions relied on clinical or procedural markers of CAD, evidence of myocardial infarction, or imaging data consistent with a CAD diagnosis (PMC3679547). The CARDIOGRAMplusC4D GWAS included 63,746 CAD cases and 130,681 controls. The meta-analysis of UKBB and CARDIOGRAMplusC4D totaled 122,733 CAD cases and 424,528 controls.

Genome-wide Association Study Data - Depression

We used summary statistics from the PGC and UKBB as the base for the MetaXcan analysis of depression²⁴. The genome-wide association meta-analysis for depression included 170,756 cases and 329,443 controls. These results included summary statistics from a metaanalysis of the 33 cohorts of the Psychiatric Genomics Consortium as described in Wray et al. (2018), (https://doi.org/10.1038/s41588-018-0090-3) and the broad depression phenotype in the full release of the UKBB as described in (Howard et al. (2018), https://doi.org/10.1038/s41467-018-03819-3). The broad depression phenotype in UKBB included self-reported help-seeking behavior for "nerves, anxiety, tension or depression (once at any visit)" from a general practice physician or a psychiatrist. Secondly, a subject was defined as a case if there was a primary or secondary diagnosis of a depressive mood disorder from linked hospital admission records (UK Biobank fields: 41202 and 41204; ICD codes: F32—Single episode depression, F33—Recurrent depression, F34—Persistent mood disorders, F38—Other mood disorders and F39—Unspecified mood disorders). The remaining respondents were classed as controls if they answered "No" to both questions on all assessments. For the PGC sample, cases were those who met international consensus criteria (DSM-IV, ICD-9, or ICD-10) for a lifetime diagnosis of MDD established using structured diagnostic instruments from assessments by trained interviewers, clinician-administered checklists, or medical record review. Controls in most samples were screened for the absence of lifetime MDD (22/29 samples) or randomly selected from the population.

Statistical Analysis of Genetic Data

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

S-MultiXcan Analysis of Depression and CAD GWAS Summary Statistics

Predicted expression models of 22,207 genes across 49 tissues were developed (supplementary materials) as previously described using data from the Genotype Tissue Expression Project^{25,26}. These models were then used to train gene-based predicted associations for each set of summary statistics described above^{25,26}. The subsequent associations with CAD and depression were tested using a multivariate regression model (Summary-MultiXcan or S-MultiXcan) which uses cross-tissue eQTL information²⁵. S-MultiXcan infers the gene-level MultiXcan association results, using univariate S-PrediXcan results and LD information from a reference panel (i.e., the GTEx data set). Correlations between tissues are accounted for using a pseudo-inverse approach which applies a singular value decomposition (SVD) of the covariance matrix to keep only the components of large variation.

We used a Bonferroni correction to adjust the statistical significance threshold for 20,971 gene-based tests in the CAD MetaXcan analysis (p < 2.38e-06) and 20,945 gene-based tests in the depression MetaXcan analysis (p < 2.38e-06).

Enrichment Analysis of Gene-based Association Results (Depression and CAD)

After identifying genes associated with either depression or CAD, we determined whether genes associated with both CAD and depression (n=185) were more abundant than expected by chance, based on the number of genes significantly associated with each phenotype independently. We performed a hypergeometric test using the hyper R package and the publicly available website http://nemates.org/MA/progs/overlap_stats.html.

Gene Set Enrichment Analyses (GSEA)

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

We used the Gene Set Enrichment Analysis Web-based Tool (http://www.gseamsigdb.org/gsea/msigdb/annotate.jsp) to functionally annotate the pathways for the 185 genes associated with both depression and CAD. We restricted our analysis to the 'canonical pathways' class with FDR q-values less than 0.05 and the GTEx compendium expression profiles. There were 2,982 pathways, composed of 40,786 genes, tested in the null 'background' set, provided by GSEA. **Description of Clinical Populations** Vanderbilt University Medical Center (VUMC) Electronic Health Record (EHR) Vanderbilt University Medical Center (VUMC) is a tertiary care center that provides inpatient and outpatient care in middle Tennessee and surrounding communities. The VUMC electronic health record (EHR) system was established in 1990 and includes data on billing codes from the International Classification of Diseases, 9th and 10th editions (ICD-9 and ICD-10), Current Procedural Terminology (CPT) codes, laboratory values, reports, and clinical documentation. A fully de-identified mirror image of the EHR, called the Synthetic Derivative, is available to Vanderbilt faculty for research purposes²⁷. Massachusetts General Brigham (MGB) EHR Mass General Brigham (MGB) is a hospital network that includes Massachusetts General Hospital, Brigham and Women's hospital, and other community and specialty hospitals in Boston area. The data source of MGB EHR is MGB Research Patient Data Registry (RPDR;

https://rpdrssl.partners.org), an EHR database which spans more than 20 years of data from

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

over 6.5 million patients and includes data on diagnoses (billing codes; ICD-9 and ICD-10 codes), procedures (CPT codes), laboratory values, and clinical notes. Data floors were applied to the MGB RPDR to include only patients with at least one clinical note and three visits since 2005 with visit more than 30 days apart. All of Us Research Program We used data from the All of Us Research Program, a multi-ancestry population-based cohort that contains various forms of information on individuals²⁸. This data repository enrolls participants 18 years of age or older and contains their demographic and medical record-based information. The data for disease diagnosis was collected using billing codes and was the converted to phecodes. Phenotypic analysis in the Synthetic Derivative Informed by results of the genomic analyses, we first investigated the prevalence of cardiomyopathy in three mutually exclusive groups of patients in the VUMC-EHR including those who had a diagnosis of (1) depression or major depression without comorbid CAD (dep), (2) CAD without comorbid depression (CAD), and (3) CAD with comorbid depression or major depression ((m)dCAD)(Table S1). To reduce missingness of clinical data and enrich the sample for patients who receive their primary care at VUMC, we applied a simple "medical home" heuristic requiring the presence of any five codes on different days over a period of at least three years. We selected the cohort of individuals meeting these criteria who also had not been

included in the VUMC BioBank which resulted in a total of 988,002 individuals. The genotyped

sample was held out of this analysis to maintain its independence for future related research studies including genomic data.

We defined dep-only, CAD-only, and (m)dCAD using phecodes which are higher order combinations of at least two related ICD codes, occurring on two different days, using the R PheWAS package. Specifically, "CAD-only" cases required the presence of phecode 411.4 and absence of 296.2 phecode (N = 47,351), "dep-only" cases included phecode 296.2 and absence of 411.4 phecode (N = 57,069) and (m)dCAD required the presence of a phecode for both CAD and depression (N = 6,725). We next calculated the prevalence of cardiomyopathy, indicated by the presence of one or more of the following phecodes "425.1", "425.11", "425.12", "425.8", "425". We then compared the prevalence of cardiomyopathy diagnoses between each diagnostic group using Pearson's Chi-squared test and Fisher's exact T-test.

We then used a logistic regression model to determine whether cardiomyopathy was indeed more prevalent among patients with (m)dCAD, compared to CAD alone, after controlling for potential confounding. Cases were defined as those with cardiomyopathy, controls were those without cardiomyopathy. The exposure was defined as depression, and features known to associate with both depression and cardiomyopathy, age, race, sex, record median BMI, type 2 diabetes (T2D; Phecode = 250.2), tobacco use disorder (TUD; Phecode = 318) and hypertension (Phecodes = 401, 415.21, 453), were included as covariates.

Next, we used the same regression-based approach to test whether *incident* cardiomyopathy was increased among individuals with (m)dCAD compared to CAD alone. All individuals with cardiomyopathy coded prior to depression or CAD (N = 14,583) were excluded. Hence the cardiomyopathy exposure was required to be coded after both depression and CAD.

This resulted in a total of 2,345 cardiomyopathy cases and 45,330 cardiomyopathy controls. We then fitted two multivariable logistic regression models to test whether depression increased the odds of incident cardiomyopathy among patients with (m)dCAD compared to patients with CAD alone, after adjusting for the same previously described confounders.

Sensitivity analyses using Severe Depression.

Previous literature points towards progression and worsening of CAD with increasing depression severity. To test whether cardiomyopathy more commonly co-occurred with severe depression, we redefined our exposure using a stricter MDD definition requiring the presence of 296.22 phecode and ICD9/10 codes (Table S8) which dropped the sample size from 57,069 depression-exposed patients to 41,423 MDD-exposed patients. The same regression models described above were fitted to the data.

Phenotypic Replication in MGB and All of Us Data

We replicated the EHR analyses in two external cohorts, *All of Us* and MGB. We used the same phecode based definitions to define our inclusion and exclusion criteria, case and control labels, and exposures. Sensitivity analyses were similarly performed in these data by restricting the exposure definition to include individuals with only severe depression.

Results

Genes Associated with Both Depression and CAD

We intersected the 22,207 predicted expression gene models with the summary statistics of CAD and depression phenotypes as described above. While the tissues that best predicted gene expression differed between CAD and depression (Figure S4); the mean (Spearman's rank = 0.433), standard deviation (Spearman's rank = 0.565), minimum (Spearman's rank = 0.389), and maximum (Spearman's rank = 0.373) association Z-score statistics demonstrated strong correlation between depression and CAD across all tissues tested (Figure S3).

Results from the 20,971 gene-based tests of association with CAD, and 20,945 gene-

Results from the 20,971 gene-based tests of association with CAD, and 20,945 gene-based tests of association with depression are available in Table S2 and Table S3, respectively^{23,24}. We identified a total of 1,455 genes significantly associated with CAD (p < 2.38e-06) and 928 genes significantly associated with depression (p < 2.38e-06) illustrated in Figures S1 and S2, respectively. We next identified the genes that were significantly associated with *both* depression and CAD. A total of 20,944 genes were tested in common between depression and CAD, and of these, 185 genes identified by their gene names were significantly associated with *both* CAD and depression (Figure 2; Table S4). The genes associated with both depression and CAD were distributed across the genome (Figure 2).

Enrichment and Pathway Analysis of 185 Genes Associated with Both Depression and CAD

We found that there were three times more genes associated with both CAD and depression than expected by chance given the number of genes significantly associated with each phenotype independently (hypergeometric test, p<1.718e-43) (Figure 3). Inflammatory

(FDR q-value < 0.05) and cardiomyopathy-associated pathways (FDR q value < 0.05) were overrepresented among genes associated with both CAD and depression (Table 1). Five genes from the shared set of 185 (2.7%) were annotated to cardiomyopathy-associated pathways. Four of the 5 genes (*ATP2A2*, *ITGB4*, *SGCD*, and *CACNB4*) were annotated to all three cardiomyopathy pathways (Table S4). Thirteen additional genes (7%) were annotated to adaptive immune pathways (Table S4).

Clinical Cardiomyopathy in (m)dCAD

Analyses performed in the EHR returned significant differences in the prevalence of cardiomyopathy between depression-only, CAD-only and (m)dCAD cohorts (Chisq P < 2.2e-16) (Table S5). Almost 15% of individuals with (m)dCAD had a cardiomyopathy diagnosis, compared to 11.2% in the CAD cohort and only 1.59 % in the depression cohort. The results remained significant when we compared only the (m)dCAD group to the CAD group (Fisher's exact test p < 2.2e-16) (Table S5). We then replicated these findings in the MGH EHR and the All of Us Data. We next restricted the depression phenotype to major depression (phecode 296.22) and observed the same pattern in the prevalence of cardiomyopathy between the groups (Table S6).

Prevalence of Clinical Cardiomyopathy after Adjusting for known Confounders

Results of the multivariable logistic model indicate that there is a 27% increase in the odds of prevalent cardiomyopathy with a diagnosis of (m)dCAD compared to CAD after adjusting for age, race, sex, hypertension diagnosis, smoking status, type-2-diabetes and BMI

(see Methods for details) (p-value = 3.6e-09, OR = 1.27, 95% CI = 1.17-1.3). This finding was replicated in the *All of Us* (p-value = 0.012, OR = 1.16, 95%CI = 1.03-1.30) and MGH (p-value < 2e-16, OR = 1.32, 95%CI = 1.28-1.37) data sets.

Sensitivity analyses restricting the criteria for depression to "major depression" preserved the effect estimate and significance of the original finding (OR = 1.14, 95%CI = 1.06-1.26, p = 6.5e-03)(Figure 4). This finding was again replicated in the MGH cohort (OR = 1.23, 95%CI = 1.13-1.18, p < 2e-16). While the effect estimate was similar in the *All of Us* data set, the finding did not reach statistical significance likely due to a reduced sample size (OR = 1.13, 95%CI = 0.97-1.32, p-value = 0.12)

Rate of Incident Cardiomyopathy in (m)dCAD compared to CAD

Lastly, we tested the hypothesis that (m)dCAD is a risk factor for the development of *subsequent* cardiomyopathy. Using a multivariable logistic regression model, we found no increase in the odds of incident cardiomyopathy among (m)dCAD patients compared to CAD patients, after adjusting for known confounders in the VUMC EHR (OR = 0.96, 95% CI = 0.84-1.09, p-value = 0.53) (Figure 5) and in the *All of Us* data (OR = 0.864, 95%C.I. = 0.730-1.021, p-value = 0.086). In the MGH data, not only did we observe a lack of evidence for increased incident cardiomyopathy subsequent to (m)dCAD, in fact we observed that (m)dCAD cases were significantly *less* likely to be diagnosed with new onset cardiomyopathy compared to CAD alone (OR = 0.783, 95%C.I. = 0.743-0.825, p-value < 2e-16).

After restricting the definition of depression to "major depression" in the VUMC data, the odds of incident cardiomyopathy were elevated but not significantly so (OR = 1.16, 95% C.I.

= 1.00-1.34, p-value = 0.04). However, again, in the *All of Us* (OR = 0.66, 95% C.I. = 0.51-0.84, p-value = 9e-4) and MGH (OR = 0.54, 95% C.I. = 0.50-0.58, p-value < 2e-16) data, the rate of incident cardiomyopathy was lower in (m)dCAD than in CAD alone.

Discussion

Depression and CAD are highly comorbid conditions and the molecular mechanisms underlying this common comorbidity remain understudied. Here we present an integrative genotypic approach to identify genes that map to SNP associations for each condition, followed by a phenotypic analysis to test a hypothesis motivated by the genetic findings. By performing a cross-tissue transcriptome-wide association scan using large scale GWAS data for depression and CAD, we identified 185 genes (three time more than expected by chance) that were significantly associated with both depression and CAD. Interestingly, the genes associated with both phenotypes were not necessarily those most strongly associated with depression or CAD independently. On balance, these results suggest that comorbid (m)dCAD may have a partially unique genetic architecture which overlaps a subset of genes associated with depression and CAD.

Pathway analyses indicate that the genes involved in (m)dCAD are enriched for inflammatory and cardiomyopathy-associated pathways. Specifically, we observed an enrichment for adaptive immune system genes which can be understood in the context of previous studies that have highlighted immune dysfunction in both depression and CAD^{15,29–36}. Moreover, research has shown that depression is associated with low-grade chronic

inflammation whereas CAD has phases of both, acute and chronic inflammation^{36–38}. Hence the enrichment of adaptive immune system genes suggests that depression and CAD could be linked through exposure to low-grade chronic inflammation.

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

There were six genes ATP2A2, ITGB4, SGCD, CACNB4, ACTN2, and TGFB1 associated with both CAD and depression, which are known to be involved in cardiomyopathy (Table S4). Differential expression of ATP2A, which encodes a Ca²⁺ pump on the endoplasmic reticulum, is associated with cardiac phenotypes including dilated cardiomyopathy^{39,,40}; and heterozygous conditional knockout mice demonstrate an essential role for ATP2A in neuronal calcium homeostasis resulting in behavioral phenotypes⁴¹. Similarly, CACNB4 is the one of the most abundant voltage-gated calcium channel subunits expressed in the brain where it is critical for presynaptic signaling, and co-located in the heart where early data suggests it may be involved in cardiac contraction^{42–44}. The gene locus was also recently implicated in idiopathic cardiomyopathy in individuals of African-American ancestry⁴⁵. ACTN2, a cardiac-specific structural protein, is classically involved in familial hypertrophic, dilated, and arrhythmogenic cardiomyopathy^{46–48} while *TGFB1* is a cytokine with a variety of cellular functions implicated in cardiac hypertrophy and hypertrophic cardiomyopathy along with congenital heart disease^{49,50}. Mutations in delta-sarcoglycan (SGCD) result in severe neuromuscular disease in humans and knockout mice develop early progressive cardiomyopathy and dilated cardiomyopathy^{51,52}. However, less is known about the impact of differences in expression of these genes (ACTN2, TGFB1, and SGCD) on depression.

Interpreted in the context of previous studies, our genetic findings suggest that depression and CAD could share low grade chronic inflammation^{36,53–55}. Moreover, genetic

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

results of our study raised the hypothesis that a predisposition to both depression and CAD (clinically observed as (m)dCAD) may further predispose individuals to cardiomyopathy. Canonically, viral infections are considered the most common trigger and cause of inflammatory cardiomyopathy thus leading to immune mechanisms which potentially damage the myocardial function^{56–63}. However, an alternative model consistent with our findings could position chronic low-grade inflammation as a shared risk factor for depression, CAD, and cardiomyopathy. We investigated the hypothesis that cardiomyopathy co-occurs more commonly with (m)dCAD than with CAD, by harnessing the power of large-scale electronic health record data at VUMC, MGB, and All of Us. These three systems represent both hospital ascertainment (VUMC and MGB) and volunteer ascertainment (All of Us). Results of these analyses suggest that while prevalent cardiomyopathy does in fact co-occur more frequently with (m)dCAD than with CAD alone, the order of events remains unclear. For example, it remains possible that (a) cardiomyopathy increases the risk of co-morbid depression in CAD, (b) treatment for depression provides some protection against subsequent cardiomyopathy, or (c) both cardiomyopathy and (m)dCAD share additional risk factors. While our work demonstrating the clinical co-occurrence suggests that cardiomyopathy patients may benefit from depression screening, future work is needed to disentangle their precise relationship and inform clinically translatable mitigation strategies. Despite its strengths, our study is limited by the well-established caveats of EHR based

Despite its strengths, our study is limited by the well-established caveats of EHR based phenotyping which itself suffers from individual bias of the clinician. TWAS analyses rely on SNP-based predictive models of mRNA trained using mostly European-ancestry individuals in GTEx v8 and assumes additivity of SNP effects on gene expression, which ignores the possibility

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

of epistatic and gene-environment interactions. Online pathway tools are prone to knowledge bias in selection of the "validated" genes annotated to pathways. Nevertheless, these analyses highlight the unique genetic and phenotypic architecture of (m)dCAD compared to CAD and depression alone. We add to the literature the observation that prevalent, but perhaps not incident cardiomyopathy, is also more common in patients with (m)dCAD compared to CAD alone. Importantly, this hypothesis was motivated by genetic findings suggesting that the genes associated with both depression and CAD are enriched for pathways with a known role in immune and cardiomyopathy-associated biological processes. This data-driven approach highlights the power of in silico transcriptome-wide studies to motivate hypotheses that can be tested in large EHR databases. Acknowledgements **Funding** KS is funded by the American Heart Association Fellowship AHA827137. LKD is supported by R56MH120736. JWS and LKD are supported in part by NIMH R01 H118233. JMS is funded by 1F31MH124306-01A1. QSW was supported by NIH 1R01HL140074. CTSA (SD, Vanderbilt Resources) The deidentified EHR used at VUMC was supported by the National Center for Research Resources, Grant UL1 RR024975-01, and is now at the National Center for Advancing

Translational Sciences, Grant 2 UL1 TR000445-06. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. BioVU The dataset(s) used for the analyses described were obtained from Vanderbilt University Medical Center's BioVU which is supported by numerous sources: institutional funding, private agencies, and federal grants. These include the NIH funded Shared Instrumentation Grant S10RR025141; and CTSA grants UL1TR002243, UL1TR000445, and UL1RR024975. Genomic data are also supported by investigator-led projects that include U01HG004798, R01NS032830, RC2GM092618, P50GM115305, U01HG006378, U19HL065962, R01HD074711; and additional funding sources listed at https://victr.vumc.org/biovu-funding/. The All of Us Research Program is supported by grants through the National Institutes of Health, Office of the Director: Regional Medical Centers: 1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA#: AOD 16037; Federally Qualified Health Centers: HHSN 263201600085U; Data and Research Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176; Participant Technology Systems Center: 1 U24 OD023163; Communications and Engagement: 3 OT2 OD023205; 3 OT2 OD023206; and Community Partners: 1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337: 1 OT2 OD025276. In addition to the funded partners, the All of Us Research *Program* would not be possible without the contributions made by its participants.

Declarations

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

Contributions K.S. and L.K.D. conceptualized and designed the work. K.S, J.M.S, and H.L. implemented the computational procedures and performed data analysis. N.J.C, Q.S.W., and E.C.H provided important clinical and intellectual insights. All authors read, edited, and approved the final manuscript. Corresponding author Correspondence to Lea K. Davis at lea.k.davis@vumc.org **Ethics declarations** Ethics approval and consent to participate This study was reviewed by the VUMC IRB and designated as non-human subjects research because of the use of fully de-identified data (IRB# 190418 and IRB# 201609). Competing interests JWS is a member of the Scientific Advisory Board of Sensorium Therapeutics (with equity), and has received an honorarium for an internal seminar Tempus Labs. He is PI of a collaborative study of the genetics of depression and bipolar disorder sponsored by 23andMe for which 23andMe provides analysis time as in-kind support but no payments. **Supplementary Materials** Supplementary Methods

Supplementary Figure 1 474 475 Supplementary Figure 2 476 Supplementary Figure 3 477 Supplementary Figure 4 478 Supplementary Table 1 479 Supplementary Table 2 480 Supplementary Table 3 481 Supplementary Table 4 482 Supplementary Table 5 483 Supplementary Table 6 484

References

- 486 1. Kendler, K. S., Gardner, C. O., Fiske, A. & Gatz, M. Major depression and coronary artery
- disease in the Swedish twin registry: phenotypic, genetic, and environmental sources of
- 488 comorbidity. *Arch. Gen. Psychiatry* **66**, 857–863 (2009).
- 489 2. Glassman, A. H. Depression and cardiovascular comorbidity. *Dialogues Clin. Neurosci.* **9**, 9–17
- 490 (2007).
- 491 3. Sullivan, M. et al. Depression in coronary heart disease. What is the appropriate diagnostic
- 492 threshold? *Psychosomatics* **40**, 286–292 (1999).
- 493 4. O'Neil, A. et al. Depression is a risk factor for incident coronary heart disease in women: An
- 494 18-year longitudinal study. J. Affect. Disord. **196**, 117–124 (2016).
- 495 5. Weeke, A., Juel, K. & Vaeth, M. Cardiovascular death and manic-depressive psychosis. J.
- 496 Affect. Disord. 13, 287–292 (1987).
- 497 6. Dennis, J. et al. Genetic risk for major depressive disorder and loneliness in sex-specific
- associations with coronary artery disease. *Mol. Psychiatry* **26**, 4254–4264 (2021).
- 7. Mazereeuw, G. et al. Platelet activating factors in depression and coronary artery disease: a
- 500 potential biomarker related to inflammatory mechanisms and neurodegeneration. *Neurosci*.
- 501 *Biobehav. Rev.* **37**, 1611–1621 (2013).
- 8. McCaffery, J. M. et al. Common genetic vulnerability to depressive symptoms and coronary
- artery disease: a review and development of candidate genes related to inflammation and
- serotonin. *Psychosom. Med.* **68**, 187–200 (2006).
- 505 9. Upadhyay, R. K. Emerging risk biomarkers in cardiovascular diseases and disorders. J. Lipids
- **2015**, 971453 (2015).

- 507 10. Shimokawa, H., Aarhus, L. L. & Vanhoutte, P. M. Porcine coronary arteries with
- regenerated endothelium have a reduced endothelium-dependent responsiveness to
- aggregating platelets and serotonin. *Circ. Res.* **61**, 256–270 (1987).
- 510 11. Brydon, L., Magid, K. & Steptoe, A. Platelets, coronary heart disease, and stress. *Brain.*
- 511 Behav. Immun. **20**, 113–119 (2006).
- 512 12. Huang, M. et al. Longitudinal association of inflammation with depressive symptoms: A
- 513 7-year cross-lagged twin difference study. *Brain. Behav. Immun.* **75**, 200–207 (2019).
- 514 13. Beydoun, M. A. et al. White blood cell inflammatory markers are associated with
- depressive symptoms in a longitudinal study of urban adults. *Transl. Psychiatry* **6**, e895
- 516 (2016).
- 517 14. Kim, J.-M. et al. Changes in pro-inflammatory cytokine levels and late-life depression: A
- two year population based longitudinal study. *Psychoneuroendocrinology* **90**, 85–91 (2018).
- 519 15. Bränn, E. et al. Inflammatory markers in late pregnancy in association with postpartum
- 520 depression-A nested case-control study. *Psychoneuroendocrinology* **79**, 146–159 (2017).
- 521 16. Bremmer, M. A. et al. Inflammatory markers in late-life depression: results from a
- 522 population-based study. J. Affect. Disord. **106**, 249–255 (2008).
- 523 17. Martínez-Cengotitabengoa, M. et al. Peripheral Inflammatory Parameters in Late-Life
- Depression: A Systematic Review. Int. J. Mol. Sci. 17, E2022 (2016).
- 525 18. Gheysarzadeh, A. et al. Serum-based microRNA biomarkers for major depression: MiR-
- 526 16, miR-135a, and miR-1202. J. Res. Med. Sci. Off. J. Isfahan Univ. Med. Sci. 23, 69 (2018).

- 527 19. Schmidt, H. D., Shelton, R. C. & Duman, R. S. Functional biomarkers of depression:
- diagnosis, treatment, and pathophysiology. *Neuropsychopharmacol. Off. Publ. Am. Coll.*
- 529 *Neuropsychopharmacol.* **36**, 2375–2394 (2011).
- 530 20. Nurden, A. T. The biology of the platelet with special reference to inflammation, wound
- healing and immunity. Front. Biosci. Landmark Ed. 23, 726–751 (2018).
- 532 21. Tsao, C.-W., Lin, Y.-S., Chen, C.-C., Bai, C.-H. & Wu, S.-R. Cytokines and serotonin
- transporter in patients with major depression. *Prog. Neuropsychopharmacol. Biol. Psychiatry*
- **30**, 899–905 (2006).
- 535 22. Pandey, G. N. et al. Hyperactive phosphoinositide signaling pathway in platelets of
- depressed patients: effect of designamine treatment. *Psychiatry Res.* **105**, 23–32 (2001).
- 537 23. van der Harst, P. & Verweij, N. Identification of 64 Novel Genetic Loci Provides an
- 538 Expanded View on the Genetic Architecture of Coronary Artery Disease. Circ. Res. 122, 433–
- 539 443 (2018).
- 540 24. Howard, D. M. et al. Genome-wide meta-analysis of depression identifies 102
- independent variants and highlights the importance of the prefrontal brain regions. *Nat.*
- 542 *Neurosci.* **22**, 343–352 (2019).
- 543 25. Barbeira, A. N. et al. Integrating predicted transcriptome from multiple tissues improves
- association detection. *PLOS Genet.* **15**, e1007889 (2019).
- 545 26. Lonsdale, J. et al. The Genotype-Tissue Expression (GTEx) project. Nat. Genet. 45, 580–
- 546 585 (2013).
- 547 27. Bowton, E. et al. Biobanks and Electronic Medical Records: Enabling Cost-Effective
- 548 Research. Sci. Transl. Med. 6, (2014).

- 549 28. The All of Us Research Program Investigators. The "All of Us" Research Program. N. Engl.
- 550 *J. Med.* **381**, 668–676 (2019).
- 551 29. McCaffery, J. M. et al. Common genetic vulnerability to depressive symptoms and
- 552 coronary artery disease: a review and development of candidate genes related to
- inflammation and serotonin. *Psychosom. Med.* **68**, 187–200 (2006).
- 554 30. Upadhyay, R. K. Emerging risk biomarkers in cardiovascular diseases and disorders. J.
- 555 *Lipids* **2015**, 971453 (2015).
- 556 31. Shimokawa, H., Aarhus, L. L. & Vanhoutte, P. M. Porcine coronary arteries with
- regenerated endothelium have a reduced endothelium-dependent responsiveness to
- aggregating platelets and serotonin. *Circ. Res.* **61**, 256–270 (1987).
- 559 32. Brydon, L., Magid, K. & Steptoe, A. Platelets, coronary heart disease, and stress. *Brain*.
- 560 Behav. Immun. **20**, 113–119 (2006).
- 561 33. Huang, M. et al. Longitudinal association of inflammation with depressive symptoms: A
- 7-year cross-lagged twin difference study. *Brain. Behav. Immun.* **75**, 200–207 (2019).
- 563 34. Beydoun, M. A. et al. White blood cell inflammatory markers are associated with
- depressive symptoms in a longitudinal study of urban adults. *Transl. Psychiatry* **6**, e895
- 565 (2016).
- 566 35. Kim, J.-M. et al. Changes in pro-inflammatory cytokine levels and late-life depression: A
- two year population based longitudinal study. *Psychoneuroendocrinology* **90**, 85–91 (2018).
- 568 36. Sealock, J. M. et al. Use of the PsycheMERGE Network to Investigate the Association
- Between Depression Polygenic Scores and White Blood Cell Count. JAMA Psychiatry 78, 1365
- 570 (2021).

- 571 37. Twig, G. et al. White Blood Cell Count and the Risk for Coronary Artery Disease in Young
- 572 Adults. *PLoS ONE* **7**, e47183 (2012).
- 38. Zebrack, J. S., Muhlestein, J. B., Horne, B. D. & Anderson, J. L. C-reactive protein and
- angiographic coronary artery disease: independent and additive predictors of risk in subjects
- 575 with angina. J. Am. Coll. Cardiol. **39**, 632–637 (2002).
- 576 39. Lu, Q. et al. Intranuclear cardiac troponin I plays a functional role in regulating Atp2a2
- 577 expression in cardiomyocytes. *Genes Dis.* S2352304221000611 (2021)
- 578 doi:10.1016/j.gendis.2021.04.007.
- 579 40. Alimadadi, A., Munroe, P. B., Joe, B. & Cheng, X. Meta-Analysis of Dilated
- 580 Cardiomyopathy Using Cardiac RNA-Seq Transcriptomic Datasets. *Genes* **11**, 60 (2020).
- 581 41. Nakajima, K. et al. Brain-specific heterozygous loss-of-function of ATP2A2, endoplasmic
- reticulum Ca2+ pump responsible for Darier's disease, causes behavioral abnormalities and a
- 583 hyper-dopaminergic state. *Hum. Mol. Genet.* **30**, 1762–1772 (2021).
- 584 42. Coste de Bagneaux, P. et al. A homozygous missense variant in CACNB4 encoding the
- auxiliary calcium channel beta4 subunit causes a severe neurodevelopmental disorder and
- impairs channel and non-channel functions. *PLOS Genet.* **16**, e1008625 (2020).
- 587 43. Andrade, A. et al. Genetic Associations between Voltage-Gated Calcium Channels and
- 588 Psychiatric Disorders. *Int. J. Mol. Sci.* **20**, 3537 (2019).
- 589 44. Kanehisa, M. et al. KEGG for linking genomes to life and the environment. Nucleic Acids
- 590 *Res.* **36**, D480–D484 (2007).
- 591 45. Xu, H. et al. A Genome-Wide Association Study of Idiopathic Dilated Cardiomyopathy in
- 592 African Americans. J. Pers. Med. 8, 11 (2018).

- 593 46. Good, J.-M. et al. ACTN2 variant associated with a cardiac phenotype suggestive of left-
- dominant arrhythmogenic cardiomyopathy. *Hear. Case Rep.* **6**, 15–19 (2020).
- 595 47. Haywood, N. J. et al. Hypertrophic cardiomyopathy mutations in the calponin-homology
- domain of ACTN2 affect actin binding and cardiomyocyte Z-disc incorporation. *Biochem. J.*
- **473**, 2485–2493 (2016).
- 598 48. Tiso, N. Identification of mutations in the cardiac ryanodine receptor gene in families
- affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). *Hum. Mol.*
- 600 Genet. **10**, 189–194 (2001).
- 601 49. Patel, R. et al. Variants of Trophic Factors and Expression of Cardiac Hypertrophy in
- Patients with Hypertrophic Cardiomyopathy. J. Mol. Cell. Cardiol. 32, 2369–2377 (2000).
- 603 50. Yadav, M. L., Bhasker, A. N., Kumar, A. & Mohapatra, B. Identification and
- characterization of genetic variants of TGFB1 in patients with congenital heart disease. *Meta*
- 605 Gene **31**, 100987 (2022).
- 606 51. Bauer, R., MacGowan, G. A., Blain, A., Bushby, K. & Straub, V. Steroid treatment causes
- deterioration of myocardial function in the -sarcoglycan-deficient mouse model for dilated
- 608 cardiomyopathy. *Cardiovasc. Res.* **79**, 652–661 (2008).
- 609 52. Rutschow, D. et al. S151A δ-sarcoglycan mutation causes a mild phenotype of
- cardiomyopathy in mice. Eur. J. Hum. Genet. **22**, 119–125 (2014).
- 53. Lynall, M.-E. et al. Peripheral Blood Cell–Stratified Subgroups of Inflamed Depression.
- 612 *Biol. Psychiatry* **88**, 185–196 (2020).
- 613 54. McNally, L., Bhagwagar, Z. & Hannestad, J. Inflammation, Glutamate, and Glia in
- 614 Depression: A Literature Review. CNS Spectr. **13**, 501–510 (2008).

- 615 55. Troubat, R. et al. Neuroinflammation and depression: A review. Eur. J. Neurosci. 53,
- 616 151–171 (2021).
- 617 56. Eitel, I. et al. Inflammation in takotsubo cardiomyopathy: insights from cardiovascular
- 618 magnetic resonance imaging. *Eur. Radiol.* **20**, 422–431 (2010).
- 619 57. Adamo, L., Rocha-Resende, C., Prabhu, S. D. & Mann, D. L. Reappraising the role of
- inflammation in heart failure. Nat. Rev. Cardiol. 17, 269–285 (2020).
- 621 58. Maisch, B., Ristic, A. D. & Pankuweit, S. [Inflammatory cardiomyopathy and
- 622 myocarditis]. *Herz* **42**, 425–438 (2017).
- 623 59. Krejci, J., Mlejnek, D., Sochorova, D. & Nemec, P. Inflammatory Cardiomyopathy: A
- 624 Current View on the Pathophysiology, Diagnosis, and Treatment. *BioMed Res. Int.* **2016**,
- 625 4087632 (2016).
- 626 60. Tschöpe, C. et al. Myocarditis and inflammatory cardiomyopathy: current evidence and
- 627 future directions. *Nat. Rev. Cardiol.* **18**, 169–193 (2021).
- 628 61. Eitel, I. et al. Clinical characteristics and cardiovascular magnetic resonance findings in
- 629 stress (takotsubo) cardiomyopathy. *JAMA* **306**, 277–286 (2011).
- 630 62. Scally, C. et al. Myocardial and Systemic Inflammation in Acute Stress-Induced
- 631 (Takotsubo) Cardiomyopathy. *Circulation* **139**, 1581–1592 (2019).
- 632 63. Rroku, A., Grahl, S., Landmesser, U. & Heidecker, B. A case report of myocardial
- inflammation in takotsubo syndrome. A chicken-or-the-egg phenomenon. Int. J. Cardiol.
- 634 *Heart Vasc.* **39**, 100958 (2022).

Figures and Tables

636

637





Figure 1


Title: Overall Schematic of the Study

Legend: We performed a transcriptome-wide association study (TWAS) of genetically regulated expression (GReX) using the GTEx v.8 database and genome-wide summary statistics of Depression and Coronary Artery Disease separately. We derived genes that were shared between Depression and CAD, we performed pathway and enrichment analyses. Our results show that genes associated with both depression and CAD are associated with cardiomyopathy associated phenotypes.



Title: Genes associated with Depression and CAD using S-MultiXcan

grouped by chromosome (x-axis) and p value (y-axis) of the association with the phenotype. The top half of the graph are genes associated with CAD and the lower half of the graph represents genes associated with Depression. The purple dots represent the 185 genes shared between Depression and CAD. Genes with –log(p values) greater that 50 are labelled. The light and dark Legend: A Miami plot of genes associated with both Depression and CAD via S-MultiXcan Each data point represents a gene grey represents the non-shared genes on alternating chromosomes with light grey with being the non-shared genes on odd chromosomes and dark grey representing the non-shared genes on the even numbered chromosomes



Genes Shared Between CAD and Depression: 185

3x Enrichment of Shared Association (hypergeometric test p < 1.718e-43

Figure 3

Title: Enrichment test of the genes shared between Depression and CAD

Legend: Eulerr Plot to highlight the results of enrichment test of the genes associated with both depression and CAD. The grey circle represents the set of 20,944 genes that were tested for association with both phenotypes. The red portion represents the 1,270 genes significantly associated with CAD only. The blue portion represents the 743 genes significantly associated with depression only. The purple portion represents the 185 genes associated with both depression and CAD. Red + purple represents all CAD associated genes (1455) and blue + purple represents all genes associated with depression (928).




Figure 4

Title: Forest plot illustrating odds of prevalent cardiomyopathy in (m)dCAD compared to CAD

Legend: The association between (m)dCAD vs CAD and prevalent cardiomyopathy after controlling for race, median age across the medical record, sex, T2D, hypertension, and smoking (ever/never) at each of the three sites (VUMC, MGB, and All of Us). Purple represents results from an analysis in which depression was broadly defined while light pink represents results from an analysis restricted to major depression. Whiskers indicate 95% CIs.




Figure 5

Title: Forest plot illustrating odds of incident cardiomyopathy in (m)dCAD compared to CAD

Legend: The association between (m)dCAD vs CAD and incident cardiomyopathy after controlling for race, median age across the medical record, sex, T2D, hypertension, and smoking (ever/never) at each of the three sites (VUMC, MGB, and All of Us). Purple represents results from an analysis in which depression was broadly defined while light pink

Gene Set Name	No. of Genes in the set (K)	Number of Genes in Overlap (k)	k/K	FDR Value
Post-translational protein modification	1435	22	0.0152	1.39e-03
Arrhythmogenic right ventricular cardiomyopathy (ARCV)	76	5	0.0657	1.87e-02
Transport of small molecules	728	13	0.0179	1.87e-02
Hypertrophic cardiomyopathy (HCM)	83	5	0.0602	2.13e-02
Dilated cardiomyopathy	90	5	0.0556	2.62e-02
Adaptive Immune System	825	13	0.0158	3.79e-02

Table 1: Gene Set Enrichment Analysis of the Shared Genes

 Legend: We used the 185 genes shared between Depression and CAD as the input for GESA (Canonical Pathways) browser and identified that the shared genes are associated with immune and cardiomyopathy associated phenotypes. K refers to the number of genes in the GSEA database for that particular pathway. k refers to the number of genes from our shared 185 gene-set in the particular pathway

	Depression (broad)	Major Depression	CAD	Depression and CAD	Major Depression and CAD
Sample sizes					
Total (N)	57,069	41,423	47,349	6,725	4,175
Cardiomyopathy	809 (1.41%)	537 (1.29%)	5,314 (11.22%)	1,001 (14.88%)	589 (14.10%)
Demographics					
Female (%)	68.64	69.1	32.86%	48.91%	47.04%
Median Age, years (IQR)	41(24.5 – 65.5)	39 (22.5 – 55.5)	(92 – 09) 89	65 (56.5-72.5)	64 (56 – 72)
Median BMI (IQR)	27.34	27.28	28.81	29.29	29.68
Underweight	2,071 (3.63%)	1,655 (4.0%)	377 (0.79%)	64 (0.95%)	39 (0.93%)
Normal	17,437 (30.56%)	12,964 (31.3%)	8,673 (18.31%)	1,320 (19.62%)	794 (19.02%)
Overweight	14,154 (24.80%)	10,204 (24.63%)	15,520 (32.77%)	1,979 (29.43%)	1,291 (30.93%)
Obese	19,247 (33.73%)	14,203 (34.28%)	17,423 (36.8%)	2,812 (41.81%)	1,951 (46.73%)
Unknown	4,160 (7.29%)	2,397 (5.78%)	5,356 (11.31%)	550 (8.18%)	100 (2.4%)
Cardiovascular Comorbidities					
Hypertension (N, %)	19,784 (34.66%)	13,513 (32.62%)	38,905 (82.17%)	6,200 (92.2%)	3,837 (91.9%)
Type 2 Diabetes (N, %)	7,452 (13.06%)	5,116 (12.35%)	15,207 (32.11%)	3,227 (47.99%)	2,062 (49.39%)
Tobacco Use Disorder (N, %)	8,363 (14.65%)	6,555 (15.82%)	8,482 (17.91%)	2,399 (35.67%)	1,816 (43.5%)

Table 2: Demographic table for Phenotypes in VUMC

This table describes the demographics for Depression, Major Depression, CAD, Comorbid Depression-CAD and Comorbid Major Depression-CAD in VUMC EHR data. 656 Supplementary Materials 657 of 658 Genes associated with depression and coronary artery disease are enriched for inflammation and cardiomyopathy-associated pathways. 659 Kritika Singh^{1,2}, Hyunjoon Lee^{3,4,5*}, Julia M Sealock^{1,2*}, Tyne Miller-Flemming^{1,2}, Peter 660 Straub^{1,2}, Nancy J. Cox^{1,2}, Quinn S. Wells⁶, Jordan M. Smoller^{3,4,5}, Emily C. Hodges^{2,7}, Lea 661 K. Davis^{1,2,8,9,10} 662 663 *These authors contributed equally 664 #Corresponding author 665 ¹Division of Genetic Medicine, Department of Medicine Vanderbilt University Medical Center 666 667 Nashville, TN, 37232, USA 668 669 ²Vanderbilt Genetics Institute 670 Vanderbilt University Medical Center 671 Nashville, TN, 37232, USA 672 673 ³Psychiatric and Neurodevelopmental Genetics Unit 674 Center for Genomic Medicine 675 Massachusetts General Hospital 676 Boston, MA, 02114, USA 677 678 ⁴Center for Precision Psychiatry 679 Department of Psychiatry 680 Massachusetts General Hospital 681 Boston, MA, 02114, USA 682 683 ⁵Stanley Center for Psychiatric Research 684 Broad Institute of Harvard and MIT 685 Cambridge, MA, 02114, USA 686 687 ⁶Division of Cardiovascular Medicine, Department of Medicine, 688 Vanderbilt University Medical Center,

689	Nashville, TN, 37232, USA
690	
691	⁷ Department of Biochemistry,
692	Vanderbilt University School of Medicine,
693	Nashville, TN, 37232, USA
694	
695	⁸ Department of Molecular Physiology and Biophysics
696	Vanderbilt University Medical Center
697	Nashville, TN, 37232, USA
698	
699	⁹ Department of Psychiatry and Behavioral Sciences
700	Vanderbilt University Medical Center
701	Nashville, TN, 37232, USA
702	
703	¹⁰ Departments of Medicine and Biomedical Informatics
704	Vanderbilt University Medical Center
705	Nashville, TN, 37232, USA
706	

Description of Clinical Populations

Vanderbilt University Medical Center (VUMC) Electronic Health Record (EHR)


Vanderbilt University Medical Center (VUMC) is a tertiary care center that provides inpatient and outpatient care in middle Tennessee and surrounding communities. The VUMC electronic health record (EHR) system was established in 1990 and includes data on billing codes from the International Classification of Diseases, 9th and 10th editions (ICD-9 and ICD-10), Current Procedural Terminology (CPT) codes, laboratory values, reports, and clinical documentation. A fully de-identified mirror image of the EHR, called the Synthetic Derivative, is available to Vanderbilt faculty for research purposes. A data floor (i.e., "medical home") heuristic of any five codes on different days over a period of at least three years was imposed to enrich the sample for primary care.

Massachusetts General Hospital (MGH)

Mass General Brigham (MGB) is a hospital network that includes Massachusetts General Hospital, Brigham and Women's hospital, and other community and specialty hospitals in Boston area. The data source of MGB EHR is MGB Research Patient Data Registry (RPDR; https://rpdrssl.partners.org), an EHR database which spans more than 20 years of data from over 6.5 million patients and includes data on diagnoses (billing codes; ICD-9 and ICD-10 codes), procedures (CPT codes), laboratory values, and clinical notes. Data floors were applied to the MGB RPDR to include only patients with at least one clinical note and three visits since 2005 with visit more than 30 days apart.


All of Us Research Program

All of Us Research Program, a population-based cohort that contains demographic, EHR, and survey information on participants. Participants enroll digitally through the All of Us website. After completion of the consent modules and enrollment, participants are given several health-measuring surveys to be completed. As of July 2019, the All of Us program had enrolled more than 175,000 core participants and more than 230,000 total participants.



Title: Genes associated with CAD using S-MultiXcan


Legend: A Miami plot of genes and SNPs associated with CAD via S-MultiXcan. Above the x-axis, each data point represents a gene grouped by chromosome (x-axis) and p value (y-axis) of the association with the phenotype. The light red and darl red are alternating colors for genes on odd and even chromosomes. Below the x-axis, each data point represents the SNPs associated with CAD from the input GWAS. Genes with -log(p values) greater that 50 are labelled. The black and grey are alternating colors for SNPs on odd and even chromosomes



Title: Genes associated with Depression using S-MultiXcan

Figure S2

represents a gene grouped by chromosome (x-axis) and p value (y-axis) of the association with the phenotype. The light red and SNPs associated with Depression from the input GWAS. Genes with -log(p values) greater that 50 are labelled. The black and dark blue are alternating colors for genes on odd and even chromosomes Below the x-axis, each data point represents the Legend: A Miami plot of genes and SNPs associated with Depression via S-MultiXcan. Above the x-axis, each data point grey are alternating colors for SNPs on odd and even chromosomes



Title: Correlation plots between the test statistics of Depression and CAD for the 185 genes associated with both the phenotypes

Legend: (a) Correlation Plot of Z Mean of Depression and CAD for the 185 genes shared between both the phenotypes (Spearman's coefficient = 0.433)

- (b) Correlation Plot of Z Standard Deviation of Depression and CAD for the 185 genes shared between both the phenotypes (Spearman's coefficient = 0.565)
- (c) Correlation Plot of Z Min of Depression and CAD for the 185 genes shared between both the phenotypes (Spearman's coefficient = 0.389)
- (d) Correlation Plot of Z Max of Depression and CAD for the 185 genes shared between both the phenotypes (Spearman's coefficient = 0.373)




Figure S4

Title: Best Predicted Tissue Distribution of Genes Associated between Depression and CAD

Legend: (a) Tissue distribution of Best Predicted Tissue for genes associated with both Depression and CAD using SMultiXcan Results of CAD

(b) Tissue distribution of Best Predicted Tissue for genes associated with both Depression and CAD using SMultiXcan Results of Depression

Best Predicted Tissue